Annexon Inc (NASDAQ:ANNX) — Market Cap & Net Worth
Market Cap & Net Worth: Annexon Inc (ANNX)
Annexon Inc (NASDAQ:ANNX) has a market capitalization of $740.57 Million ($740.57 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10470 globally and #2715 in its home market, demonstrating a -11.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Annexon Inc's stock price $4.52 by its total outstanding shares 163842538 (163.84 Million). Review ANNX liabilities breakdown to assess the company's total debt and financial obligations.
Annexon Inc Market Cap History: 2020 to 2026
Annexon Inc's market capitalization history from 2020 to 2026. Data shows change from $4.10 Billion to $740.57 Million (-20.70% CAGR).
Index Memberships
Annexon Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.03% | #281 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1061 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.04% | #165 of 263 |
Weight: Annexon Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Annexon Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Annexon Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANNX by Market Capitalization
Companies near Annexon Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Annexon Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Annexon Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Annexon Inc's market cap moved from $4.10 Billion to $ 740.57 Million, with a yearly change of -20.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $740.57 Million | -9.96% |
| 2025 | $822.49 Million | -2.14% |
| 2024 | $840.51 Million | +13.00% |
| 2023 | $743.85 Million | -12.19% |
| 2022 | $847.07 Million | -55.00% |
| 2021 | $1.88 Billion | -54.10% |
| 2020 | $4.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Annexon Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $740.57 Million USD |
| MoneyControl | $740.57 Million USD |
| MarketWatch | $740.57 Million USD |
| marketcap.company | $740.57 Million USD |
| Reuters | $740.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more